Form 4: Immuneering Director Increases Stake Through Open Market Purchases

Immuneering Corp. Director Diana Hausman acquired 5,500 shares of Class A Common Stock through open market purchases, signaling increased insider confidence.

Summary

• Diana Hausman, a Director of Immuneering Corp. (IMRX), reported transactions involving the company's Class A Common Stock.
• On July 2, 2025, she directly acquired 2,500 shares of Class A Common Stock at a price of $3.5956 per share.
• On the same date, an additional 3,000 shares of Class A Common Stock were indirectly acquired by her spouse at a price of $3.6245 per share.
• Following these transactions, Diana Hausman beneficially owns a total of 5,500 shares of Class A Common Stock.
• The transactions were executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 8

Explanation: The acquisition of additional shares by a director indicates strong insider confidence in the company's valuation and future performance, which is generally viewed positively by the market.

Positives

• Director Diana Hausman increased her beneficial ownership in Immuneering Corp. by acquiring 5,500 shares of Class A Common Stock, signaling insider confidence.
• The purchases were made on the open market, reflecting a direct investment at prevailing market prices.
• The transactions were conducted under a Rule 10b5-1(c) plan, suggesting a structured and pre-planned investment approach.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Acquisition of 3,000 Class A Common Stock shares by the reporting person's spouse at $3.6245 per share.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal of management's belief in the company's future, potentially influencing investor sentiment.

Key Dates

Recommendation

Keywords

Immuneering Corp, IMRX, insider trading, Form 4, director, stock purchase, beneficial ownership, Class A Common Stock, Rule 10b5-1